Jefferies Financial Group Reaffirms “Buy” Rating for GSK (LON:GSK)

GSK (LON:GSK)‘s stock had its “buy” rating reiterated by research analysts at Jefferies Financial Group in a note issued to investors on Thursday,London Stock Exchange reports. They presently have a GBX 2,500 price objective on the stock. Jefferies Financial Group’s price objective indicates a potential upside of 30.16% from the company’s current price.

A number of other equities research analysts also recently issued reports on the stock. Shore Capital Group reiterated a “buy” rating on shares of GSK in a research report on Wednesday, March 25th. Citigroup cut their target price on shares of GSK from GBX 2,250 to GBX 2,100 and set a “neutral” rating for the company in a research report on Wednesday, May 6th. Berenberg Bank reiterated a “hold” rating and issued a GBX 2,000 target price on shares of GSK in a research report on Thursday, March 26th. Finally, Deutsche Bank Aktiengesellschaft reiterated a “hold” rating and issued a GBX 1,900 target price on shares of GSK in a research report on Wednesday. Two equities research analysts have rated the stock with a Buy rating, four have issued a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Hold” and an average target price of GBX 2,034.29.

GSK Stock Down 1.0%

GSK stock opened at GBX 1,920.79 on Thursday. GSK has a 12-month low of GBX 1,288.61 and a 12-month high of GBX 2,282. The company has a quick ratio of 0.73, a current ratio of 0.79 and a debt-to-equity ratio of 106.74. The company has a market cap of £76.68 billion, a price-to-earnings ratio of 13.52, a PEG ratio of 1.24 and a beta of 0.30. The company has a 50 day moving average of GBX 2,004.93 and a two-hundred day moving average of GBX 1,950.73.

GSK (LON:GSK) last released its earnings results on Wednesday, April 29th. The company reported GBX 46.50 earnings per share (EPS) for the quarter. GSK had a net margin of 17.78% and a return on equity of 35.78%. The company had revenue of GBX 762.90 billion during the quarter. On average, equities analysts anticipate that GSK will post 175.980975 earnings per share for the current fiscal year.

Insider Transactions at GSK

In other GSK news, insider Jonathan Symonds purchased 5,000 shares of the company’s stock in a transaction dated Friday, March 20th. The shares were bought at an average price of GBX 1,951 per share, for a total transaction of £97,550. Also, insider Anne Beal purchased 196 shares of the company’s stock in a transaction dated Friday, March 20th. The shares were acquired at an average price of GBX 5,179 per share, for a total transaction of £10,150.84. Insiders have acquired a total of 9,619 shares of company stock worth $19,452,794 in the last 90 days. 0.20% of the stock is owned by insiders.

GSK Company Profile

GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, and specialty and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through two segments, Commercial Operations and Total R&D. The company offers shingles, meningitis, respiratory syncytial virus, flu, polio, influenza, and pandemic vaccines. It also provides medicines for HIV, oncology, respiratory/immunology, and other specialty medicine products, as well as inhaled medicines for asthma and chronic obstructive pulmonary disease, and antibiotics for infections.